W
Weiyi Peng
Researcher at University of Houston
Publications - 71
Citations - 6908
Weiyi Peng is an academic researcher from University of Houston. The author has contributed to research in topics: Immunotherapy & Immune system. The author has an hindex of 25, co-authored 54 publications receiving 5362 citations. Previous affiliations of Weiyi Peng include Center for Cell and Gene Therapy & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng,Jie Qing Chen,Chengwen Liu,Shruti Malu,Caitlin Creasy,Michael T. Tetzlaff,Chunyu Xu,Jodi A. McKenzie,Chunlei Zhang,Xiaoxuan Liang,Leila Williams,Wanleng Deng,Guo Chen,Rina M. Mbofung,Alexander J. Lazar,Carlos A. Torres-Cabala,Zachary A. Cooper,Pei-Ling Chen,Trang N. Tieu,Stefani Spranger,Xiaoxing Yu,Chantale Bernatchez,Marie-Andree Forget,Cara Haymaker,Rodabe N. Amaria,Jennifer L. McQuade,Isabella C. Glitza,Tina Cascone,Haiyan S. Li,Lawrence N. Kwong,Timothy P. Heffernan,Jianhua Hu,Roland L. Bassett,Marcus Bosenberg,Scott E. Woodman,Willem W. Overwijk,Gregory Lizée,Jason Roszik,Thomas F. Gajewski,Jennifer A. Wargo,Jeffrey E. Gershenwald,Laszlo Radvanyi,Michael A. Davies,Patrick Hwu +43 more
TL;DR: It is demonstrated that loss of PTEN in tumor cells in preclinical models of melanoma inhibits T cell-mediated tumor killing and decreases T-cell trafficking into tumors, and support the rationale to explore combinations of immunotherapies and PI3K-AKT pathway inhibitors.
Journal ArticleDOI
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
Dennie T. Frederick,Adriano Piris,Alexandria P. Cogdill,Zachary A. Cooper,Cecilia Lezcano,Cristina R. Ferrone,Devarati Mitra,Andrea Boni,Lindsay P. Newton,Chengwen Liu,Weiyi Peng,Ryan J. Sullivan,Donald P. Lawrence,F. Stephen Hodi,Willem W. Overwijk,Gregory Lizée,George F. Murphy,Patrick Hwu,Keith T. Flaherty,David E. Fisher,Jennifer A. Wargo +20 more
TL;DR: Treatment with BRAF inhibition enhances melanoma antigen expression and facilitates T-cell cytotoxicity and a more favorable tumor microenvironment, providing support for potential synergy of BRAF-targeted therapy and immunotherapy.
Journal ArticleDOI
Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.
Gyangyong Peng,Zhong Guo,Yukiko Kiniwa,Kui Shin Voo,Weiyi Peng,Tihui Fu,Daniel Y. Wang,Yanchun Li,Helen Yicheng Wang,Rongfu Wang +9 more
TL;DR: Adoptive transfer of TLR8 ligand-stimulated Treg cells into tumor-bearing mice enhanced anti-tumor immunity and suggest that TLR 8 signaling could play a critical role in controlling immune responses to cancer and other diseases.
Journal ArticleDOI
Persistent antigen at vaccination sites induces tumor-specific CD8 + T cell sequestration, dysfunction and deletion
Yared Hailemichael,Zhimin Dai,Nina Jaffarzad,Yang Ye,Miguel A. Medina,Xue Fei Huang,Stephanie Dorta-Estremera,Nathaniel Greeley,Nathaniel Greeley,Giovanni Nitti,Giovanni Nitti,Weiyi Peng,Chengwen Liu,Yanyan Lou,Zhiqiang Wang,Wencai Ma,Brian Rabinovich,Kimberly S. Schluns,Richard E. Davis,Patrick Hwu,Willem W. Overwijk +20 more
TL;DR: Data show that persisting vaccine depots can induce specific T cell sequestration, dysfunction and deletion at vaccination sites; short-lived formulations may overcome these limitations and result in greater therapeutic efficacy of peptide-based cancer vaccines.
Journal ArticleDOI
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Weiyi Peng,Chengwen Liu,Chunyu Xu,Yanyan Lou,Jieqing Chen,Yan Yang,Hideo Yagita,Willem W. Overwijk,Gregory Lizée,Laszlo Radvanyi,Patrick Hwu +10 more
TL;DR: Results imply that blocking the PD-1 pathway can increase IFN-γ at the tumor site, thereby increasing chemokine-dependent trafficking of immune cells into malignant disease sites.